CADL - CIK 0001841387
The table below shows Candel Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $194.83M | $86.96M | $100.69M | $92.17M | $16.56M | $21.45M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $197.75M |
| $90.13M |
| $103.61M |
| $93.15M |
| $18.09M |
| $22.73M |
| Property, plant & equipment | $2.08M | $1.36M | $1.66M | $1.97M | $2.48M | $2.72M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $201.92M | $93.60M | $105.97M | $95.91M | $21.52M | $26.48M |
| Accounts payable | $3.04M | $1.12M | $1.95M | $760.00K | $296.00K | $433.00K |
| Total current liabilities | $7.05M | $10.93M | $14.71M | $20.07M | $15.27M | $14.00M |
| Long-term debt | - | - | - | - | $4.22M | $6.71M |
| Total liabilities | $63.89M | $13.47M | $15.76M | $21.23M | $36.77M | $36.46M |
| Retained earnings | -$239.25M | -$200.89M | -$189.62M | -$184.83M | -$178.13M | -$167.49M |
| Total equity | $138.03M | $80.12M | $90.21M | $74.67M | -$15.26M | -$9.97M |